Feasibility Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Stage III Melanoma Patients

Trial Profile

Feasibility Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Stage III Melanoma Patients

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Malignant melanoma; Skin cancer
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Acronyms OpACIN
  • Most Recent Events

    • 12 Sep 2017 Results of 18 months RFS update and biomarker analyses presented at the 42nd European Society for Medical Oncology Congress
    • 17 Jul 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Dec 2017.
    • 06 Jun 2017 Preliminary results pooled from four neoadjuvant therapy clinical trials (NCT02437279, NCT02231775, NCT02519322, NCT01972347; n=58), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top